{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:57:44Z","timestamp":1790629064988,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03805-y","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:41:38Z","timestamp":1790581298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-Indication Budget Impact Analysis of Subcutaneous IgPro20 Pre-filled Syringes for the Treatment of Primary Immunodeficiency Syndromes, Secondary Immunodeficiencies, and Chronic Inflammatory Demyelinating Polyneuropathy in Italy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1277-8285","authenticated-orcid":false,"given":"Batyrkhan","family":"Kuatov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Priest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Undreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melike Inkaya","family":"Taskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marcellusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"3805_CR1","unstructured":"European Observatory on Health Systems and Policies. Italy Health system summary; 2024. [Available from: https:\/\/eurohealthobservatory.who.int\/publications\/i\/italy-health-system-summary-2024."},{"key":"3805_CR2","unstructured":"Banks H, Carminati F, Furnari A, Guerra F, Longo F, Palvarini A, et al. Executive summary: 2023 OASI REPORT Observatory on Healthcare Organizations and Policies in Italy. Milan; 2023."},{"issue":"1","key":"3805_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12873-024-01112-9","volume":"24","author":"F Signorini","year":"2024","unstructured":"Signorini F, Nattino G, Rossi C, Ageno W, Catania F, Cortellaro F, et al. Measuring the crowding of emergency departments: an assessment of the NEDOCS in Lombardy, Italy, and the development of a new objective indicator based on the waiting time for the first clinical assessment. BMC Emerg Med. 2024;24(1):196.","journal-title":"BMC Emerg Med"},{"issue":"1","key":"3805_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08339-x","volume":"22","author":"M Marsilio","year":"2022","unstructured":"Marsilio M, Roldan ET, Salmasi L, Villa S. Operations management solutions to improve ED patient flows: evidence from the Italian NHS. BMC Health Serv Res. 2022;22(1):974.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"3805_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s12026-016-8784-z","volume":"64","author":"V Modell","year":"2016","unstructured":"Modell V, Quinn J, Orange J, Notarangelo LD, Modell F. Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network. Immunol Res. 2016;64(3):736\u201353.","journal-title":"Immunol Res"},{"issue":"16","key":"3805_CR6","first-page":"1","volume":"17","author":"Health Quality Ontario","year":"2017","unstructured":"Health Quality Ontario. Home-based subcutaneous infusion of immunoglobulin for primary and secondary immunodeficiencies: a health technology assessment. Ont Health Technol Assess Ser. 2017;17(16):1\u201386.","journal-title":"Ont Health Technol Assess Ser"},{"key":"3805_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-018-0290-5","volume":"14","author":"C McCusker","year":"2018","unstructured":"McCusker C, Upton J, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2018;14:1\u201312.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3805_CR8","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10875-020-00844-0","volume":"40","author":"V Lougaris","year":"1999","unstructured":"Lougaris V, Pession A, Baronio M, Soresina A, Rondelli R, Gazzurelli L, et al. The Italian registry for primary immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): twenty years of experience (1999\u20132019). J Clin Immunol. 1999;40:1026\u201337.","journal-title":"J Clin Immunol"},{"issue":"6","key":"3805_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.anai.2021.08.413","volume":"127","author":"KS Tuano","year":"2021","unstructured":"Tuano KS, Seth N, Chinen J. Secondary immunodeficiencies: an overview. Ann Allergy Asthma Immunol. 2021;127(6):617\u201326.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"3805_CR10","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1016\/j.jaci.2009.08.040","volume":"125","author":"J Chinen","year":"2010","unstructured":"Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol. 2010;125(2):S195\u2013203.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3805_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/10428194.2017.1347931","volume":"59","author":"AM Williams","year":"2018","unstructured":"Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C, et al. Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. Leuk Lymphoma. 2018;59(3):625\u201332.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3805_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bjh.15146","volume":"181","author":"KR Crassini","year":"2018","unstructured":"Crassini KR, Zhang E, Balendran S, Freeman JA, Best OG, Forsyth CJ, et al. Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. Br J Haematol. 2018;181(1):97\u2013101.","journal-title":"Br J Haematol"},{"issue":"12","key":"3805_CR13","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.3324\/haematol.2015.126763","volume":"100","author":"A Visentin","year":"2015","unstructured":"Visentin A, Compagno N, Cinetto F, Imbergamo S, Zambello R, Piazza F, et al. Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica. 2015;100(12):e515\u20138.","journal-title":"Haematologica"},{"issue":"4","key":"3805_CR14","first-page":"275","volume":"71","author":"P Meza-Meneses","year":"2019","unstructured":"Meza-Meneses P, Cornejo-Juarez P, Vilar-Compte D, Volkow-Fernandez P. Infectious complications as a predictor of mortality in patients with non-Hodgkin lymphoma receiving rituximab-containing chemotherapy. Rev Invest Clin. 2019;71(4):275\u201382.","journal-title":"Rev Invest Clin"},{"issue":"4","key":"3805_CR15","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1002\/ajh.23932","volume":"90","author":"MO Holmstrom","year":"2015","unstructured":"Holmstrom MO, Gimsing P, Abildgaard N, Andersen NF, Helleberg C, Clausen NA, et al. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: a study based on the nationwide Danish Myeloma Database. Am J Hematol. 2015;90(4):E73\u20134.","journal-title":"Am J Hematol"},{"issue":"4","key":"3805_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007","volume":"13","author":"W Wong","year":"2018","unstructured":"Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS ONE. 2018;13(4):e0196007.","journal-title":"PLoS ONE"},{"issue":"9","key":"3805_CR17","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1080\/03007995.2020.1784120","volume":"36","author":"C Waweru","year":"2020","unstructured":"Waweru C, Kaur S, Sharma S, Mishra N. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. Curr Med Res Opin. 2020;36(9):1481\u201395.","journal-title":"Curr Med Res Opin"},{"key":"3805_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11940-013-0229-6","volume":"15","author":"MM Dimachkie","year":"2013","unstructured":"Dimachkie MM, Barohn RJ. Chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol. 2013;15:350\u201366.","journal-title":"Curr Treat Options Neurol"},{"issue":"9","key":"3805_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","volume":"90","author":"HC Lehmann","year":"2019","unstructured":"Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019;90(9):981\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"23","key":"3805_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1212\/WNL.0000000000006625","volume":"91","author":"H Koike","year":"2018","unstructured":"Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, et al. Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology. 2018;91(23):1051\u201360.","journal-title":"Neurology"},{"issue":"3","key":"3805_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40120-025-00732-y","volume":"14","author":"A Roberts","year":"2025","unstructured":"Roberts A, Griffiths N, Thiara K, Wallace S, Young AL, Williamson N, et al. Patient Experience of chronic inflammatory demyelinating polyneuropathy (CIDP): a qualitative exploration of signs, symptoms, and health-related quality of life impacts. Neurol Therapy. 2025;14(3):1039\u201359.","journal-title":"Neurol Therapy"},{"issue":"10","key":"3805_CR22","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","volume":"268","author":"L Querol","year":"2021","unstructured":"Querol L, Crabtree M, Herepath M, Priedane E, Viejo Viejo I, Agush S, et al. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2021;268(10):3706\u201316.","journal-title":"J Neurol"},{"issue":"12","key":"3805_CR23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1136\/jnnp.2007.114868","volume":"78","author":"A Chi\u00f2","year":"2007","unstructured":"Chi\u00f2 A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007;78(12):1349\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3805_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1575464","volume":"16","author":"M Caballero-\u00c1vila","year":"2025","unstructured":"Caballero-\u00c1vila M, Martin-Aguilar L, Collet-Vidiella R, Querol L, Pascual-Go\u00f1i E. A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy. Front Immunol. 2025;16:1575464.","journal-title":"Front Immunol"},{"key":"3805_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381","volume":"14","author":"MC Dalakas","year":"2021","unstructured":"Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:1756286421997381.","journal-title":"Ther Adv Neurol Disord"},{"key":"3805_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3389\/fimmu.2014.00674","volume":"5","author":"SQ Nagelkerke","year":"2015","unstructured":"Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol. 2015;5:674.","journal-title":"Front Immunol"},{"issue":"4","key":"3805_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1423-0410.2009.01217.x","volume":"97","author":"M Spycher","year":"2009","unstructured":"Spycher M, Matozan K, Minnig K, Zehnder R, Miescher S, Hoefferer L, et al. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations. Vox Sang. 2009;97(4):348\u201354.","journal-title":"Vox Sang"},{"issue":"1","key":"3805_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02834.x","volume":"142","author":"S Jolles","year":"2005","unstructured":"Jolles S, Sewell W, Misbah S. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142(1):1\u201311.","journal-title":"Clin Exp Immunol"},{"issue":"Supplement_1","key":"3805_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","volume":"158","author":"S Misbah","year":"2009","unstructured":"Misbah S, Sturzenegger M, Borte M, Shapiro R, Wasserman R, Berger M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158(Supplement_1):51\u20139.","journal-title":"Clin Exp Immunol"},{"key":"3805_CR30","unstructured":"CSL Behring. Hizentra: Summary of Product Characteristics; 2011."},{"key":"3805_CR31","unstructured":"CSL Behring. Hizentra Prescribing Information. [Available from: https:\/\/labeling.cslbehring.com\/PI\/US\/Hizentra\/EN\/Hizentra-Prescribing-Information.pdf."},{"key":"3805_CR32","unstructured":"CSL Behring. Hizentra - Summary of product characteristics. [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hizentra-epar-product-information_en.pdf."},{"issue":"12","key":"3805_CR33","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/17425247.2018.1546692","volume":"15","author":"AR Kafal","year":"2018","unstructured":"Kafal AR, Vinh DC, Langelier MJ. Prefilled syringes for immunoglobulin G (IgG) replacement therapy: clinical experience from other disease settings. Expert Opin Drug Deliv. 2018;15(12):1199\u2013209.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"3805_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10837450.2014.982825","volume":"20","author":"G Sacha","year":"2015","unstructured":"Sacha G, Rogers JA, Miller RL. Pre-filled syringes: a review of the history, manufacturing and challenges. Pharm Dev Technol. 2015;20(1):1\u201311.","journal-title":"Pharm Dev Technol"},{"key":"3805_CR35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.26452\/ijrps.v11iSPL4.3763","volume":"11","author":"SA Borse","year":"2020","unstructured":"Borse SA, Gorle AP, Patil K. Prefilled syringe: a review of injectable dosage form delivery system. Int J Pharma Sci Res. 2020;11:167\u201374.","journal-title":"Int J Pharma Sci Res"},{"issue":"1","key":"3805_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12865-024-00608-0","volume":"25","author":"R Mallick","year":"2024","unstructured":"Mallick R, Solomon G, Bassett P, Zhang X, Patel P, Lepeshkina O. Subcutaneous immunoglobulin replacement therapy in patients with immunodeficiencies\u2013impact of drug packaging and administration method on patient reported outcomes. BMC Immunol. 2024;25(1):18.","journal-title":"BMC Immunol"},{"issue":"1","key":"3805_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-024-00939-y","volume":"21","author":"R Mallick","year":"2025","unstructured":"Mallick R, Hahn N, Scalchunes C. Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction. Allergy Asthma Clin Immunol. 2025;21(1):1\u201312.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3805_CR38","unstructured":"Mallick R et al. A budget impact model (BIM) of treatment of primary immune deficiency (PID) with IgPro 20 (Hizentra) relative to subcutaneous immunoglobulins (SCIGs) and intravenous immunoglobulins (IVIGs); 2022."},{"issue":"7","key":"3805_CR39","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/jnnp-2014-310280","volume":"87","author":"D Cocito","year":"2016","unstructured":"Cocito D, Merola A, Romagnolo A, Peci E, Toscano A, Mazzeo A, et al. Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response? J Neurol Neurosurg Psychiatry. 2016;87(7):791\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"3805_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1756285614563056","volume":"8","author":"RD Hadden","year":"2015","unstructured":"Hadden RD, Marreno F. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction. Ther Adv Neurol Disord. 2015;8(1):14\u20139.","journal-title":"Ther Adv Neurol Disord"},{"key":"3805_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","volume":"26","author":"U Nicolay","year":"2006","unstructured":"Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65\u201372.","journal-title":"J Clin Immunol"},{"issue":"9","key":"3805_CR42","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1177\/10600280231212890","volume":"58","author":"D Benhamou","year":"2024","unstructured":"Benhamou D, Weiss M, Borms M, Lucaci J, Girgis H, Frolet C, et al. Assessing the clinical, economic, and health resource utilization impacts of prefilled syringes versus conventional medication administration methods: results from a systematic literature review. Ann Pharmacother. 2024;58(9):921\u201334.","journal-title":"Ann Pharmacother"},{"key":"3805_CR43","unstructured":"AIFA Medicines - Italian Medicines Agency. HIZENTRA 200 mg\/ml SOLUZIONE INIETTABILE. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000046446."},{"key":"3805_CR44","unstructured":"AIFA Medicines - Italian Medicines Agency. PRIVIGEN 100 mg\/ml SOLUZIONE PER INFUSIONE. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000043610."},{"key":"3805_CR45","unstructured":"AIFA Medicines - Italian Medicines Agency. GAMMAGARD 50 mg\/ml POLVERE E SOLVENTE PER SOLUZIONE PER INFUSIONE ENDOVENOSA. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000030887."},{"key":"3805_CR46","unstructured":"AIFA Medicines - Italian Medicines Agency. OCTAGAM 5 % SOLUZIONE PER INFUSIONE. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000034587."},{"key":"3805_CR47","unstructured":"AIFA Medicines - Italian Medicines Agency. GAMTEN 100 mg\/ml SOLUZIONE PER INFUSIONE. ENDOVENOSA [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000043212."},{"key":"3805_CR48","unstructured":"AIFA Medicines - Italian Medicines Agency. FLEBOGAMMA DIF 100 mg\/ml SOLUZIONE PER INFUSIONE. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000044694."},{"key":"3805_CR49","unstructured":"AIFA Medicines - Italian Medicines Agency. FLEBOGAMMA DIF 50 mg\/ml SOLUZIONE PER INFUSIONE. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000044693."},{"key":"3805_CR50","unstructured":"AIFA Medicines - Italian Medicines Agency. IG VENA 50 g\/l SOLUZIONE PER INFUSIONE ENDOVENOSA. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000015655."},{"key":"3805_CR51","unstructured":"AIFA Medicines - Italian Medicines Agency. KIOVIG 100 mg\/ml SOLUZIONE PER INFUSIONE. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000038584."},{"key":"3805_CR52","unstructured":"AIFA Medicines - Italian Medicines Agency. IQYMUNE 100 mg\/ml SOLUZIONE PER INFUSIONE ENDOVENOSA. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000051184."},{"key":"3805_CR53","unstructured":"AIFA Medicines - Italian Medicines Agency. GAMUNEX 100 mg\/ml SOLUZIONE PER INFUSIONE ENDOVENOSA. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000054478."},{"key":"3805_CR54","unstructured":"AIFA Medicines - Italian Medicines Agency. GLOBIGA 100 mg\/ml SOLUZIONE PER INFUSIONE. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000052046."},{"key":"3805_CR55","unstructured":"AIFA Medicines - Italian Medicines Agency. CUVITRU 200 mg\/ml SOLUZIONE INIETTABILE. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000052213."},{"key":"3805_CR56","unstructured":"AIFA Medicines - Italian Medicines Agency. CUTAQUIG 165 mg\/ml SOLUZIONE INIETTABILE. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000055432."},{"key":"3805_CR57","unstructured":"AIFA Medicines - Italian Medicines Agency. HYQVIA 100 mg\/ml SOLUZIONE PER INFUSIONE. [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000049401."},{"key":"3805_CR58","unstructured":"AIFA Medicines - Italian Medicines Agency. NAXIGLO 160 mg\/ml SOLUZIONE PER INFUSIONE [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000050447."},{"key":"3805_CR59","unstructured":"AIFA Medicines - Italian Medicines Agency. XEMBIFY 200 MG\/ML SOLUZIONE PER INIEZIONE SOTTOCUTANEA [Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000060445."},{"key":"3805_CR60","unstructured":"Ministry of Health. Ministry of Health decree of November 25, 2024:I NFUSIONE DI IMMUNOGLOBULINE ENDOVENA (code 99.14.1). [Available from: https:\/\/www.trovanorme.salute.gov.it\/norme\/renderNormsanPdf?anno=2024&codLeg=104476&parte=1%20&serie=null."},{"key":"3805_CR61","unstructured":"CSL Behring. PRIVIGEN\u00ae Immune Globulin Intravenous (Human), 10% Liquid, for intravenous use. 2007."},{"issue":"2","key":"3805_CR62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/jns5.12017","volume":"18","author":"JM L\u00e9ger","year":"2013","unstructured":"L\u00e9ger JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, et al. Efficacy and safety of Privigen\u00ae in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). J Peripher Nerv Syst. 2013;18(2):130\u201340.","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"3805_CR63","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s10875-010-9423-4","volume":"30","author":"JB Hagan","year":"2010","unstructured":"Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734\u201345.","journal-title":"J Clin Immunol"},{"issue":"5","key":"3805_CR64","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000590","volume":"6","author":"IN Van Schaik","year":"2019","unstructured":"Van Schaik IN, Mielke O, Bril V, Van Geloven N, Hartung H-P, Lewis RA, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019;6(5):e590.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8905","key":"3805_CR65","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","volume":"343","author":"H Chapel","year":"1994","unstructured":"Chapel H, Lee M, Hargreaves R, Pamphilon D, Prentice A. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet. 1994;343(8905):1059\u201363.","journal-title":"Lancet"},{"key":"3805_CR66","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.","journal-title":"Front Immunol"},{"key":"3805_CR67","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40261-018-0688-3","volume":"38","author":"R Viti","year":"2018","unstructured":"Viti R, Marcellusi A, Capone A, Matucci A, Vultaggio A, Pignata C, et al. Direct and indirect costs of immunoglobulin replacement therapy in patients with common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA) in Italy. Clin Drug Investig. 2018;38:955\u201365.","journal-title":"Clin Drug Investig"},{"key":"3805_CR68","unstructured":"Bank; EC. Inflation and consumer prices [Available from: https:\/\/www.ecb.europa.eu\/stats\/macroeconomic_and_sectoral\/hicp\/html\/index.en.html."},{"key":"3805_CR69","doi-asserted-by":"crossref","unstructured":"Mallick R, Carlton R. A Budget Impact Model of Treatment of Primary Immune Deficiency with Immune Globulin Subcutaneous (Human), 20%(IgPro20)(Hizentra) R. Mallick, R. Carlton. PharmacoEconomics-Open. 2025:1\u201312.","DOI":"10.1007\/s41669-025-00594-y"},{"issue":"2","key":"3805_CR70","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s41669-023-00386-2","volume":"7","author":"R Mallick","year":"2023","unstructured":"Mallick R, Carlton R, Van Stiphout J. A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States. PharmacoEconomics-Open. 2023;7(2):243\u201355.","journal-title":"PharmacoEconomics-Open"},{"key":"3805_CR71","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s10072-014-1632-9","volume":"35","author":"C Lazzaro","year":"2014","unstructured":"Lazzaro C, Lopiano L, Cocito D. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis. Neurol Sci. 2014;35:1023\u201334.","journal-title":"Neurol Sci"},{"issue":"2","key":"3805_CR72","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2249.2009.04079.x","volume":"160","author":"J Beaute","year":"2010","unstructured":"Beaute J, L\u00e9vy P, Millet V, Debre M, Dudoit Y, Le Mignot L, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160(2):240\u20135.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"3805_CR73","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s10875-016-0288-z","volume":"36","author":"C Perraudin","year":"2016","unstructured":"Perraudin C, Bourdin A, Spertini F, Berger J, Bugnon O. Switching patients to home-based subcutaneous immunoglobulin: an economic evaluation of an interprofessional drug therapy management program. J Clin Immunol. 2016;36(5):502\u201310.","journal-title":"J Clin Immunol"},{"issue":"2","key":"3805_CR74","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.anai.2017.11.002","volume":"120","author":"LW Fu","year":"2018","unstructured":"Fu LW, Song C, Isaranuwatchai W, Betschel S. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: a prospective economic analysis. Ann Allergy Asthma Immunol. 2018;120(2):195\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"e1","key":"3805_CR75","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1136\/ejhpharm-2020-002430","volume":"28","author":"E Piscitelli","year":"2021","unstructured":"Piscitelli E, Massa M, De Martino BM, Serio CS, Guglielmi G, Colacicco G, et al. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study. Eur J Hosp Pharm. 2021;28(e1):e115\u20139.","journal-title":"Eur J Hosp Pharm"},{"key":"3805_CR76","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S544296","author":"M Borms","year":"2025","unstructured":"Borms M, Taneja A, Weiss M, Girgis H, Frolet C, Lucaci JD. Improving efficiency and safety with prefilled syringes: a model-based economic evaluation for US healthcare settings. Clinicoecon Outcomes Res. 2025. https:\/\/doi.org\/10.2147\/CEOR.S544296.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"12","key":"3805_CR77","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.1016\/j.jval.2023.09.1574","volume":"26","author":"D Mehta","year":"2023","unstructured":"Mehta D, Kimball-Carroll S, Krivelyova A, Lai K, Van de Velde N. HSD22 vaccine preparation time, cost, and preference comparison between pre-filled syringe formulations and vaccines that require reconstitution: a targeted literature review. Value Health. 2023;26(12):S298.","journal-title":"Value Health"},{"key":"3805_CR78","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S303279","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F, Allen JA. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adherence. 2021. https:\/\/doi.org\/10.2147\/PPA.S303279.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3805_CR79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/ene.14034","volume":"27","author":"A Raggi","year":"2020","unstructured":"Raggi A, Leonardi M, Sansone E, Curone M, Grazzi L, D\u2019Amico D. The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patient-derived data. Eur J Neurol. 2020;27(1):62-e1.","journal-title":"Eur J Neurol"},{"key":"3805_CR80","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S501716","author":"L Prosperini","year":"2025","unstructured":"Prosperini L, Pradelli L, Santoni L, Perini D, Cottone S, Vercellino M. Cost-minimization analysis and budget impact analysis about subcutaneous natalizumab in relapsing-remitting multiple sclerosis in Italy. Clinicoecon Outcomes Res. 2025. https:\/\/doi.org\/10.2147\/CEOR.S501716.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"3805_CR81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00520-006-0094-x","volume":"15","author":"E Ballatori","year":"2007","unstructured":"Ballatori E, Roila F, Ruggeri B, Porrozzi S, Iannopollo M, Soru G, et al. The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer. 2007;15(1):31\u20138.","journal-title":"Support Care Cancer"},{"key":"3805_CR82","doi-asserted-by":"publisher","DOI":"10.1177\/11297298251345989","author":"F Pinelli","year":"2025","unstructured":"Pinelli F, Firenzuoli F, Romagnoli S, Mazzella M, Matarrese D, Bianco E, et al. Intracavitary ECG versus X-ray guidance for central venous access device tip location: a cost-effectiveness analysis. J Vasc Access. 2025. https:\/\/doi.org\/10.1177\/11297298251345989.","journal-title":"J Vasc Access"},{"key":"3805_CR83","unstructured":"Mandolfo S, Maggio M, Forneris G, Galli F. Cost analysis of haemodialysis catheter related bloodstream infection through the DRG system,\" on behalf of Project Group of Vascular Access of Italian Society of Nephrology. G Ital Nefrol. 2019;36(1)."},{"issue":"1","key":"3805_CR84","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.thromres.2012.10.008","volume":"131","author":"G Gussoni","year":"2013","unstructured":"Gussoni G, Foglia E, Frasson S, Casartelli L, Campanini M, Bonfanti M, et al. Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients. Thromb Res. 2013;131(1):17\u201323.","journal-title":"Thromb Res"},{"key":"3805_CR85","unstructured":"FASIE. Tariffario 2022\/2023: Medicazione ambulatoriale di ferita chirurgica (minor surgical wound care performed in an outpatient surgical clinic) [Available from: https:\/\/www.fasie.it\/wp-content\/uploads\/2024\/06\/Tariffario-2022_2023.pdf."},{"key":"3805_CR86","doi-asserted-by":"crossref","unstructured":"Roggeri DP, Roggeri A, Pengo V. Il Trattamento del tromboembolismo venoso: analisi di budget impact di rivaroxaban in Italia. Health economics and therapeutic pathways; 2014.","DOI":"10.7175\/fe.v15i4.968"},{"issue":"12","key":"3805_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121380","volume":"9","author":"M Astengo","year":"2021","unstructured":"Astengo M, Paganino C, Amicizia D, Trucchi C, Tassinari F, Sticchi C, et al. Economic burden of pneumococcal disease in individuals aged 15 years and older in the Liguria region of Italy. Vaccines (Basel). 2021;9(12):1380.","journal-title":"Vaccines (Basel)"},{"key":"3805_CR88","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S442906","author":"S Di Matteo","year":"2024","unstructured":"Di Matteo S, Freilone R, Bruno GM, Notaro R, Moumene S, Martone N, et al. Cost-utility analysis comparing pegcetacoplan to anti-C5 monoclonal antibodies in the treatment of paroxysmal nocturnal hemoglobinuria. Clinicoecon Outcomes Res. 2024. https:\/\/doi.org\/10.2147\/CEOR.S442906.","journal-title":"Clinicoecon Outcomes Res"},{"key":"3805_CR89","unstructured":"GBS CIDP Foundation International. GBS\/CIDP patient survey [Available from: https:\/\/www.gbs-cidp.org."},{"key":"3805_CR90","doi-asserted-by":"crossref","unstructured":"Maki DG, Kluger DM, Crnich CJ, editors. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies; 2006.","DOI":"10.4065\/81.9.1159"},{"issue":"8","key":"3805_CR91","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/01.NAJ.0000282299.03441.c7","volume":"107","author":"L Hadaway","year":"2007","unstructured":"Hadaway L. Infiltration and extravasation. AJN Am J Nurs. 2007;107(8):64\u201372.","journal-title":"AJN Am J Nurs"},{"issue":"6","key":"3805_CR92","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.thromres.2014.03.046","volume":"133","author":"E Ram\u00edrez","year":"2014","unstructured":"Ram\u00edrez E, Romero-Garrido JA, L\u00f3pez-Granados E, Borobia AM, P\u00e9rez T, Medrano N, et al. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. Thromb Res. 2014;133(6):1045\u201351.","journal-title":"Thromb Res"},{"issue":"21","key":"3805_CR93","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/blood.V124.21.2884.2884","volume":"124","author":"V Bharath","year":"2014","unstructured":"Bharath V, Eckert K, Kang M, Chin-Yee I, Hsia CC. Incidence and natural history of IVIG-induced aseptic meningitis: a retrospective review at a single tertiary care centre. Blood. 2014;124(21):2884.","journal-title":"Blood"},{"issue":"8","key":"3805_CR94","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/j.1537-2995.2008.01721.x","volume":"48","author":"Z Daw","year":"2008","unstructured":"Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. 2008;48(8):1598\u2013601.","journal-title":"Transfusion"},{"key":"3805_CR95","unstructured":"European Union. Hourly labour costs, 2024 [Available from: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=File:Hourly_labour_costs,_2024_(%E2%82%AC),_map_rev3.png."},{"issue":"12","key":"3805_CR96","doi-asserted-by":"publisher","first-page":"S434","DOI":"10.1016\/j.jval.2022.09.2163","volume":"25","author":"A Molinari","year":"2022","unstructured":"Molinari A, Gorsh B, Perera S, Budhiarso I, Chen J, Skalicky A. PCR230 understanding the indirect burden of patients and caregivers impacted by refractory\/relapsing multiple myeloma. Value Health. 2022;25(12):S434.","journal-title":"Value Health"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03805-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:03:34Z","timestamp":1790625814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03805-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":96,"alternative-id":["3805"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03805-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"10 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alanna MacDonald, Stacey Priest, and Diana Tran are employees of EVERSANA. CSL Behring contracted EVERSANA to conduct this study. Batyrkhan Kuatov, Laurence Undreiner, and Melike Inkaya Taskin are employees of CSL Behring. Sara Villa was an employee of CSL Behring at the time of her contributions. Batyrkhan Kuatov and Melike Inkaya Taskin hold stock in CSL Behring. Andrea Marcellusi has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants, identifiable personal health information, or biological specimens. The budget impact model was developed using publicly available, aggregate data sources, with the exception of non\u2011protected market share data that contained no identifiable or sensitive information. In accordance with institutional and national guidelines, and given the use of fully non\u2011identifiable secondary data, this research did not require review or approval by a research ethics board. No ethical approval was sought or required.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time this study was conducted, Sara Villa was affiliated with CSL Behring. Sara Villa is now employed by AstraZeneca.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}